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Abstract
Background: The SCN5A gene encodes for the a-subunit of the cardiac sodium channel NaV1.5, which is responsible for the
rapid upstroke of the cardiac action potential. Mutations in this gene may lead to multiple life-threatening disorders of
cardiac rhythm or are linked to structural cardiac defects. Here, we characterized a large family with a mutation in SCN5A
presenting with an atrioventricular conduction disease and absence of Brugada syndrome.
Method and Results: In a large family with a high incidence of sudden cardiac deaths, a heterozygous SCN5A mutation
(p.1493delK) with an autosomal dominant inheritance has been identified. Mutation carriers were devoid of any cardiac
structural changes. Typical ECG findings were an increased P-wave duration, an AV-block Iu and a prolonged QRS duration
with an intraventricular conduction delay and no signs for Brugada syndrome. HEK293 cells transfected with 1493delK
showed strongly (5-fold) reduced Na+ currents with altered inactivation kinetics compared to wild-type channels.
Immunocytochemical staining demonstrated strongly decreased expression of SCN5A 1493delK in the sarcolemma
consistent with an intracellular trafficking defect and thereby a loss-of-function. In addition, SCN5A 1493delK channels that
reached cell membrane showed gain-of-function aspects (slowing of the fast inactivation, reduction in the relative fraction
of channels that fast inactivate, hastening of the recovery from inactivation).
Conclusion: In a large family, congregation of a heterozygous SCN5A gene mutation (p.1493delK) predisposes for
conduction slowing without evidence for Brugada syndrome due to a predominantly trafficking defect that reduces Na+
current and depolarization force.
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Introduction
The SCN5A gene is located on the short arm of chromosome 3
(3p21), contains 28 exons and encodes for the a-subunit of the
cardiac sodium channel (NaV1.5), that has a weight of ,220 kDa
and consists of 2,016 amino acids [1,2,3]. The NaV1.5 a-subunit is
the pore-forming component of the NaV1.5 channel and contains
four homologous transmembrane domains (DI to DIV) joined by
three linkers. Each of the domains consists of six transmembrane
segments (S1 to S6) linked by intra- or extracellular loops [4,5,6].
S4 is positively charged and is involved in voltage-dependent
activation of the channel, while inactivation is mediated mainly by
the DIII–DIV linker [4]. NaV1.5 is responsible for the upstroke
(phase 0) of the action potential of cardiac cells. Opening of the
channel leads to a rapid influx of positive charged Na+ ions (INa),
which will depolarize the membrane potential within tenths of a
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millisecond [7]. INa plays a central role in the initiation,
propagation, as well as cardiac excitation of the cardiac impulse
[8]. Overall, the cardiac sodium channel is a multiprotein complex
in which auxiliary proteins interact with a-subunit (NaV1.5)
encompassing enzymes, regulatory proteins and adaptor proteins
that modulate gating properties, cellular localization, regulate
intracellular transport, targeting and degradation of NaV1.5 [5,7].
NaV1.5 channels are located in the sarcolemma of atrial and
ventricular myocytes, the Purkinje fibers and to a lesser extent in
the sinoatrial and atrioventricular node [6]. Mutations in SCN5A
lead to various arrhythmogenic diseases, e.g. long QT syndrome
(LQTS; subform LQT-3), Brugada syndrome (BrS; BrS-1), cardiac
conduction disease (CCD, also known as Lev-Lene`gre syndrome),
but also idiopathic atrial fibrillation, sinus node dysfunction, atrial
standstill, and even dilated cardiomyopathy (DCM)
[9,10,11,12,13,14,15,16,17]. This emphasizes the phenotypical
heterogeneity of SCN5A mutations, and overlapping clinical and
in-vitro phenotypes [18]. The basic cause is a change in NaV1.5
expression and biophysical properties leading to a loss-of-function
or gain-of-function by various mechanisms. Interestingly, overlap
syndromes have also been reported, primarily for SCN5A
mutations leading to BrS [16,19,20,21].
Here we investigated functional consequences of the 1493delK
SCN5A mutation, which was identified in a clinically characterised
large family with a high incidence of sudden cardiac deaths (SCD).
The positively charged lysine residue is located in the DIII–DIV
linker, close to the inactivation particle, and is expected to
modulate sodium channel fast inactivation.
Methods
Ethics Statement
This study was approved by the Ethics Committee of the
University Hospital Mu¨nster (Mu¨nster, Germany) and conforms to
the principles outlined in the Declaration of Helsinki [22]. All
probands and their relatives who participated in the study gave
written informed consent before genetic and clinical investigations.
Study Population
Detailed clinical data, including cardiac symptoms, device
implantation, standard 12-lead ECGs, and cardiac imaging
(transthoracic echocardiography, magnetic resonance imaging
with gadolinium contrast, or ventriculography) were obtained.
ECG analysis was performed mainly upon conventional 12-lead
ECG recordings with standard lead positions (paper speed 25 or
50 mm/s). Recordings were digitalized by scanning in a high-
resolution format and were imported into a graphic program
(DatInfH Measure, Germany) for accurate measurements. Dura-
tion of the PQ, QRS and QT intervals as well as RR intervals for
calculating the heart rate were measured in three consecutive beats
and provided as mean values. ECG and arrhythmia analyses were
independently performed by two cardiologists.
Genetic Analysis
Genetic analysis was performed as previously described [23]. In
brief, after isolation of genomic DNA, all 28 exons and adjacent
intronic sequences of the cardiac sodium channel gene (SCN5A)
were analysed by sequencing (ABI3500, Applied Biosystems,
Germany) after directed and selective PCR amplification using
standard procedures. Obtained nucleotide sequences were com-
pared with published wild-type sequences (nucleotide sequence:
GenBank, NM_000335; protein sequence: Swiss-Prot, entry
Q14524). Identified sequence variations were cross-checked for
their occurrence in the SNP database of NCBI (http://www.ncbi.
nlm.nih.gov/projects/SNP), the Exome Variant Server (http://
evs.gs.washington.edu/EVS/), disease specific mutation databases
(http://www.fsm.it/cardmoc/; http://www.genomed.org/lovd/
lqts/home.php?select_db = SCN5A) and PUBMED entries.
DNA from 380 healthy, unrelated individuals was used to
demonstrate absence in a control sample.
Heterologous Expression of Cardiac NaV1.5 Channels
SCN5A cDNA was cloned into the pCGI vector for bicistronic
expression of NaV1.5 and green fluorescent protein, as described
previously [24]. Human embryonic kidney (HEK293) cells were
transiently transfected with 0.5 mg of wild-type (WT) or 1493delK
mutant Na+ channel a-subunit cDNA, together with 0.5 mg hb1-
subunit cDNA (kindly provided by J.R. Balser, Vanderbilt
University, Nashville, Tenn) using lipofectamine (Gibco BRL,
Life Technologies). Transfected HEK293 cells were cultured for 1
or 2 days, as described previously [25]. Only cells exhibiting green
fluorescence were selected for electrophysiological experiments.
Electrophysiology and Data Analysis
Sodium currents were measured at room temperature (23uC) in
the whole-cell configuration of the patch-clamp technique using an
Axopatch 200B amplifier (Axon Instruments) and the following
solutions (in mmol/L): bath (external) solution: NaCl 140, KCl
4.7, CaCl2 1.8, MgCl2 2.0, NaHCO3 4.3, Na2HPO4 1.4, glucose
11, and HEPES 16.8, pH adjusted to 7.4 (NaOH); and pipette
(internal) solution: CsF 100, CsCl 40, EGTA 10, NaCl 10, MgCl2
1.2, and HEPES 10, pH adjusted to 7.3 (NaOH). Patch electrodes
were pulled from borosilicate glass and had a tip resistance of 2
MV when filled with pipette solution. Series resistance was
compensated for $80%. For current density measurements, all
cells were included. For measurements of gating properties,
adequate voltage control was ascertained by the presence of a
graded slope of the (in)activation curve (Boltzmann slope factors:
.4.5 and .4.0 for activation and inactivation, respectively).
Experiments were further excluded from analysis when peak
Figure 1. Pedigree of the family 10021. Men are denoted by squares and women by circles. Solid symbols indicate mutation carriers, symbols
with an ‘‘N’’ means wild type and ‘‘?’’ possible affected, crossed symbols denotes patients, who are already dead. A ‘‘-‘‘ at the symbols indicates that
no DNA is available, the propositus is marked with an arrow.
doi:10.1371/journal.pone.0067963.g001
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sodium current amplitudes at220 mV were,0.6 nA or.10 nA.
Currents were filtered at 5 kHz and digitized at 20 kHz. Voltage
control, data acquisition, and analysis were performed with a
custom-made software (kindly provided by A.C.G. van Ginneken
and J.G. Zegers). Voltage-dependence of activation and steady-
state inactivation, recovery from inactivation, and development of
slow inactivation were determined using voltage-clamp protocols
depicted in the relevant figures. In all protocols, a holding
potential of 2120 mV and a cycle time of 5 s was used. Voltage-
dependence of activation and inactivation curves were fitted with a
Boltzmann function (y= [1+ exp{(V2V1/2)/k}]21), where V1/2 is
the half-maximal voltage of (in)activation, and k is the slope factor.
Recovery from inactivation was assessed with a double-pulse
protocol. Data were normalized to the current elicited by the first
pulse (P1) and fitted with a bi-exponential function (y= y0+
Af{12exp[2t/tf]}+As{12exp[2t/ts]}), where Af and As represent
the amplitudes of the fast and the slow components of recovery
from inactivation, respectively, and tf and ts are their respective
recovery time constants. INa decay was fitted with a bi-exponential
function (y= y0+ Afexp[2t/tf]+Asexp[2t/ts]), where Af and As are
the amplitudes of the fast and the slow inactivating components,
respectively, and tf and ts are their respective inactivation time
constants. Development of slow inactivation was fitted with a
single exponential function y=A+A0exp2t/t, where t is the time
constant for the development of slow inactivation, and A is the
fraction of channels that enter the slow-inactivated state after a
1000 ms depolarization step.
Immunocytochemistry
Transfected HEK293 cells were grown on glass coverslips
coated with 0.1% laminin. Before fixation, coverslips with cultured
cells attached were rinsed in serum-free medium, fixed in 4%
paraformaldehyde (PFA) for 15 min at room temperature (RT),
and washed wit phosphate buffered saline (PBS). Next, cells were
incubated in 0.1% Triton X-100 in PBS for 30 min at RT. Cells
were then washed twice with PBS and blocked with 2% BSA (in
PBS) for 30 min at RT. Primary antibodies anti-NaV1.5 (1:300)
and anti-calnexin (1:500) were added to each coverslip and
incubated overnight at RT. After washing 3 times with PBS and
blocking in 2% BSA for 30 min, cells were incubated with the
secondary antibody for 90 min (both at RT). After 3 additional
washings with PBS, the coverslips were embedded over glass slides
using glycerol. Confocal imaging was performed using the Leica
SPE confocal laser scanning microscope (scanning enlargement
40X with additional 3X digital zoom. For dual labeling
experiments, dual color red and green images were recorded.
Antibodies
Anti-NaV1.5 (Alomone Laboratories, ASC-005) is a rabbit
polyclonal antibody raised against a peptide corresponding to
residues 492–511 of rH1. The mouse monoclonal anti-calnexin
antibody (Chemicon International, MAB3126) was used for
labeling of endoplasmic reticulum (ER). Alexa conjugated goat
anti- mouse and anti-rabbit antibodies (Molecular Probes,
Invitrogen) were used as secondary antibodies.
Statistical Analysis
Results are expressed as mean6SEM. Comparisons were made
using unpaired Student’s t-test or Mann–Whitney test when data
were not normally distributed, and two-way ANOVA with
repetitive measurements followed by a Holm–Sidak test for post-
hoc analysis, where appropriate. p,0.05 indicates statistical
significance.
Results
Clinical Data and Molecular Genetics
In a large family (family ID: 10021) with 182 members (Figure 1)
and a high incidence of sudden cardiac death (n = 8), a genetic and
clinical screening was performed in 30 patients. In 10 cases of this
patient group (4 males, 6 females; mean age 56.2616.5 years), a
novel heterozygous SCN5A mutation (c.4477–4479delAAG;
p.1493delK) with an autosomal dominant inheritance was
identified. This mutation was previously assigned as p.1479delK
[23] and later corrected into p.1493delK [26]. From 6 additional
affected family members DNA for genetic analysis was not
available, but they were obligate mutation carriers. At the protein
level, the mutation is predicted to cause an in-frame deletion of a
lysine at position 1493 of the NaV1.5 open reading frame due to a
loss of the nucleotide triplet AAG at position 4477 to 4479
(Figure 2A). This amino acid residue is located in the linker
between the domains DIII S6 and DIV S1 that is known to be
responsible for the inactivation of the channel [27]. In addition,
this mutation was not detected in 380 European control samples
and neither in .12,000 alleles screened in the setting of the
NHLBI Go Exome Sequencing Project (Exome Variant Server,
Seattle, WA; URL: http://evs.gs.washington.edu/EVS/[accessed
February 2013]). The lysine residue at position 1493 was shown to
be orthologous highly conserved. Brief clinical information of the
identified mutation carriers as well as the obligate mutation
carriers is presented in Table 1. Overall, the 10 mutation carriers
showed no signs for gross structural heart disease by transthoracic
echocardiography, magnetic resonance imaging or left/right
ventriculography [28]. Ajmaline challenge performed in six
patients proven to carry the SCN5A mutation, did not elicit a
Brugada type I-ECG that is diagnostic for BrS. However, all
mutation carriers showed signs of CCD in rest ECG (Figure 2B).
An increased P-wave duration (122.1611.1 ms in lead II,
119.7615.8 ms in lead V2 and 122.1619.8 in lead V5; normal
50–100 ms) was identified in all patients (Table 2) and an
intraventricular conduction delay in 9 out of 10 patients
characterized by prolonged QRS intervals (112.9624.1 ms in
lead II, 130.3622.5 ms in lead V2 and 114.7621.4 ms in V5) and
with no signs for right or left fascicular block (except for patient
(10021_47). Furthermore, 5 out of 10 mutation carriers presented
with an AV-block Iu (194.4619.9 ms in lead II, 188.9624.5 ms in
lead V2, 190.8627.7 ms in lead V5).
In the group with the obligate mutation carriers (2 males, 4
females; mean age 60.0615.1 years) SCD - defined as an
unexpected death due to cardiac cause, without known cardiac
diseases and under the age of 50 years - occurred in 3 cases. In one
of these cases (10021_158, proband) an ECG was available, in
which a wide P-wave (101 ms in lead II and lead V2) and an
intraventricular conduction delay (QRS interval 109 ms in lead II,
127 ms in lead V2 and 112 ms in lead V5) without classical signs
for right or left fascicular block was documented. However, this
ECG was recorded nearly 18 years before SCD occurred and
cardiac conduction slowing may have further worsened in the
course of time. In summary, mutation carriers showed cardiac
conduction delay but no signs for Brugada syndrome (ajmaline
challenge inconspicuous, Figure 2C) or repolarisation disturbance
(normal QTc intervals).
Electrophysiological Characterization of 1493delK Mutant
Sodium Channels
To assess the functional consequences of the 1493delK
mutation, sodium current (INa) biophysical properties were
determined in HEK293 cells expressing wild-type (WT) and
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Figure 2. Clinical and genetic characterization. (A) Electropherogram of SCN5Amutation c.4477–4479delAAG and multiple sequence alignment
of amino acids of human SCN5A protein regions bearing the identified in-frame deletion mutation of lysine (p.1492delK) with corresponding SCN5A
amino acid sequences of different species. (B) Electrocardiogram of patient 10021_49 shows an atrioventricular block first-degree, an increased P-
wave duration and an intraventricular conduction delay (P interval 145 ms, PQ interval 208 ms, QRS interval 146 ms). (C) Ajmaline challenge of
patient 10021_149, overall 54 mg ajmaline (1mg/kg) was administered within 5 minutes. No Brugada type I ECG could be unmasked, but cardiac
conduction delay aggravated.
doi:10.1371/journal.pone.0067963.g002
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1493delK mutant sodium channels. Results are summarized in
Table 3. Comparison of WT and 1493delK mutant peak INa
recorded during step depolarization (Figure 3A), and the
corresponding average current–voltage (I–V) relationships
(Figure 3C), clearly reveal smaller current magnitudes for
1493delK mutant channels. The average amplitude of the
maximum peak INa was 5.660.8 nA (n= 14) for WT and
2.860.5 nA (n= 16) for 1493delK mutant channels (Figure 3C,
Table 3). Inclusion of all experiments, i.e. also experiments with
INa ,0.6 nA and .10 nA (see Methods: data analysis) amounted
to a five-fold reduction in INa at 220 mV for 1493delK mutant
INa as compared to WT (Figure 3D, WT: 6.761.3 nA vs.
1493delK: 1.360.3 nA). Investigation of the voltage-dependence
of activation and steady-state inactivation did not reveal significant
differences between WT and 1493delK mutant sodium channels.
The half-maximal voltage V1/2 of activation and inactivation was
similar in both groups, with a slight increase of the slope factor k
(Figure 4E, Table 3).
Since the DIII–DIV linker has been shown [29] to be
responsible for channel fast inactivation, the deletion of a charged
residue from this region is likely to affect inactivation kinetics. In
Figures 4A and 3B, the time-dependent properties of the fast
inactivation process are summarized. Close inspection of the
1493delK current tracings in Figure 3B suggests a slowing of
inactivation, which was further supported by fitting the time
course of current decay at various voltages with a bi-exponential
function. The 1493delK mutant sodium channels displayed a
remarkable and atypical voltage dependence of the inactivation
time constants (Figure 4A-i). While fast (tf) and slow (ts) time
constants of current inactivation of WT sodium channels are
typically decreased on incremental depolarization, inactivation
time constants of 1493delK mutant sodium channels were
increased. Although tf in 1493delK is smaller at 250 mV, there
is a cross-over at 240 mV from where on tf exceeds that of WT
sodium channels, thus decreasing inactivation rate. The ts of
inactivation in 1493delK was similarly affected, but with a less
negative cross-over voltage of 220 mV. In addition to slowing the
inactivation rate, the 1493delK mutant also affected the relative
contribution of the fast inactivation component to the overall time
course of current decay. Figure 4A-ii shows the ratio - expressed as
a quotient - of the amplitudes of the fast and the slow inactivating
components (Af and As) as a function of voltage. In case of WT
sodium channels, time course of current decay is largely
determined by the fast inactivating component, constituting
,75% of total INa (Figure 4A-ii). The 1493delK mutation strongly
reduced the contribution of the fast component to the inactivation
time course, giving rise to a decrease in the ratio of Af/As at 0 mV
from 4.260.6 (WT, n= 14) to 1.360.1 (1493delK, n= 16). In
summary, the overall effect of the 1493delK mutation on
Figure 3. 1493delK mutant and wild-type (WT) human cardiac sodium channel current expressed in HEK293 cells. (A) Whole-cell
sodium current traces in response to increasing step depolarizations in WT (left) and 1493delK (right). (B) Voltage protocols for activation and steady-
state inactivation. (C) Averaged sodium current– voltage relation for WT and 1493delK sodium channels. (D) Bar histogram showing averaged WT and
1493delK sodium peak currents at 220 mV. (E) Average voltage-dependence of activation and steady-state inactivation for wild-type (WT) and
1493delK sodium channels. For the activation curve, normalized peak conductance was plotted as a function of the membrane potential. For the
inactivation curve, peak sodium currents were normalized to maximum values in each cell and plotted as a function of the voltage of the
conditioning step.
doi:10.1371/journal.pone.0067963.g003
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inactivation parameters is a profound slowing of the inactivation
rate.
Additionally, we determined the rate of recovery from
inactivation at2120 mV using a two-pulse protocol. The recovery
time course of inactivation was significantly accelerated for
1493delK sodium channels as compared to WT sodium channels
(Figure 4B, Table 3). This was exclusively due to a reduction in tf
value for 1493delK sodium channels (1493delK: tf = 3.860.4 ms
vs. WT: tf = 8.961.2 ms); values of ts were comparable
(1493delK: ts = 82.5665.3 ms vs. WT: ts = 93.2624.9 ms).
On sustained depolarization, cardiac sodium channels tend to
enter a ‘slow’ or ‘intermediate’ state of inactivation [30]. This
conformational state is distinct from the fast inactivation state,
requiring a prolonged period of hyperpolarization to recover from.
Consequently, the slow inactivation process may influence channel
availability at fast heart rates [24]. Investigation of the develop-
ment of slow inactivation revealed that the fraction of channels (A)
that slow inactivated at the end of a 1000 ms depolarization step
was significantly reduced for 1493delK sodium channels (A
= 0.22, calculated as 1 minus normalized INa) with respect to WT
sodium channels (A = 0.37) (Figure 4C, Table 3). Besides, the
1493delK mutation was also responsible for a 4.5-fold decrease in
the rate of development of slow inactivation (t) (Figure 4C,
Table 3).
Summarizing, the kinetic changes observed for the 1493delK
mutant sodium channel, i.e. a reduction of both the fast and slow
inactivation rate and a hastening of recovery from inactivation,
will lead to a gain-of-function.
Immunocytochemistry of SCN5A-wild-type and SCN5A-
1493delK
To establish whether the reduction in INa peak amplitude
reflects a reduction in the number of channels in the plasma
membrane or is due to the presence of a population of non-
functional channels, immunocytochemical analysis was performed
in HEK293 cells expressing with WT and 1493delK sodium
channels. Transfected HEK293 cells were stained with antibodies
against the cardiac sodium channel protein NaV1.5 and the
endoplasmic reticulum (ER) transmembrane protein calnexin.
Cells transfected with WT SCN5A showed a clearly distinguishable
rim of NaV1.5 staining surrounding the intracellular calnexin
staining, indicating successful trafficking of sodium channels to the
cell surface (Figure 5). In contrast, cells transfected with 1493delK
mutant SCN5A showed little discernable membrane labelling, but
merely diffuse intracellular staining for NaV1.5, which showed a
similar pattern as ER protein calnexin. Thus, these results indicate
that the 1493delK mutation causes reduced peak sodium current
by interfering with normal trafficking of sodium channels to the
cell membrane.
Discussion
Here we report on a large family with a high rate of SCD and a
SCN5A mutation (p.1493delK) that is located within the linker
region between the domains DIII and DIV, which is responsible
for the inactivation of the channel [27]. Mutations in SCN5A have
been associated with various electrical heart diseases including
LQTS [9], BrS [10], sinus node dysfunction [15], atrial fibrillation
[13,14], atrial standstill [16] and (progressive) CCD [11,12,23]. In
general, SCN5A mutations leading to a decrease in sodium current
(loss-of-function) have been associated with conduction slowing
and therefore genetically linked primarily to BrS and (progressive)
CCD [6]. Gain-of-function mutations in SCN5A are typically
associated with LQTS. Although initially the different SCN5A
mutations were linked to separate disorders, meanwhile numerous
reports have shown that a single sodium channel mutation may
inflict various combinations of clinical phenotypes of these
disorders [31,32,33].
Clinical Phenotype of 1493delK Mutation Carriers
The identified SCN5A p.1493delK mutation carriers showed no
signs of LQTS or BrS phenotype (even after ajmaline challenge),
but clear incidence of CCD consisting of increased P-wave
duration, AV-block Iu and/or intraventricular conduction slowing
in 12-lead rest ECG. Overall, five patients received an ICD for
primary prevention and one patient a pacemaker. The pacemaker
was implanted at the age of 38 years due to sick sinus syndrome
and sinus arrest, 10 years later the patient died suddenly. Since the
exact circumstances are unclear, ventricular arrhythmia cannot be
ruled out. Also, in one (10021_154) out of the five patients with an
implanted ICD, a ventricular arrhythmia occurred, which was
terminated by an ICD shock. Overall gross structural changes
were not seen in SCN5A mutation carriers [28]. Taking together,
the identified SCN5A p.1493delK mutation leads to CCD,
ventricular arrhythmias and SCD, in the absence of signs of BrS
or LQTS.
Biophysical Properties and Membrane Expression of
1493delK Mutant Sodium Channels
To investigate the correlation between the clinical and genetic
findings, electrophysiological studies were performed. Patch clamp
analyses of HEK293 cells transfected with SCN5A 1493delK
showed 5-fold reduced peak INa with altered inactivation kinetics
compared to WT transfected cells. Whereas equilibrium properties
of inactivation (and activation) were not affected, there was a
profound reduction in fast inactivation rate, as well as a reduction
in the fraction of channels that fast inactivated. The ‘‘intermedi-
ate’’ or ‘‘slow’’ inactivation process was similarly affected.
Table 3. Electrophysiological characteristics of WT and
1493delK mutant sodium channels in HEK293 cells.
WT 1493delK
INa amplitude (nA): (n = 16) (n = 21)
At 220 mV –6.761.3 –1.360.3*
Activation: (n = 14) (n = 16)
V1/2 (mV) –40.761.1 –39.561.7
k (mV) 6.260.3 7.560.4*
Steady-state inactivation: (n = 13) (n = 14)
V1/2 (mV) –92.562.4 –94.062.3
k (mV) –6.360.4 –7.560.3*
Recovery from inactivation: (n = 10) (n = 10)
tf (ms) 8.961.2 3.860.4*
ts (ms) 93.2624.9 82.866.4
Development of slow inactivation:(n = 9) (n = 11)
t (ms) 182.3622.3 825.86197.5*
A (ms) 0.3760.04 0.2260.4*
V1/2, voltage of half-maximal (in)activation; k, slope factor of voltage-
dependence of (in)activation; A, fraction of channels that enter the slow
inactivated state at t = 1 s; t, time constant for development of slow
inactivation; tf, fast time constant of recovery from inactivation; ts, slow time
constant of recovery from inactivation.
*p,0.05 vs WT (Student’s t-test).
doi:10.1371/journal.pone.0067963.t003
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Moreover, the deletion of K1493 produced a hastening of the
recovery from inactivation. In theory, all these kinetic changes will
lead to an increase of sodium current, and thus cannot account for
the significant decrease in 1493delK current amplitude we
observed.
Immunostaining experiments further identified that wild type
NaV1.5 was homogenously expressed within the sarcolemma,
whereas 1493delK NaV1.5 was primarily located intracellularly,
displaying a similar expression pattern as the endoplasmic
reticulum (ER) marker calnexin (Figure 5). This presumes a
trafficking defect comprising premature degradation of the greater
Figure 4. Inactivation kinetics of 1493delK mutant and wild-type (WT) human cardiac sodium channels. (A) Time course of current
decay. (A-i) Fast and slow time constants of current decay for WT and 1493delK sodium channels are plotted as a function of membrane potential.
Asterisks indicate statistical significance (p,0.05). (A-ii) Ratio of the amplitudes of fast and slow inactivation time constants plotted as a function of
voltage for WT and 1493delK sodium channels. (B) Time course of recovery from inactivation for WT and 1493delK sodium channels. Peak sodium
currents elicited by P2 were normalized (P2/P1) and plotted as a function of the recovery interval. Inset: 2-pulse protocol. (C) Development of slow
inactivation for WT and 1493delK sodium channels. Peak sodium currents elicited by P2 were normalized (P2/P1) and plotted as a function of the
duration of the conditioning step (P1). Inset: 2-pulse protocol.
doi:10.1371/journal.pone.0067963.g004
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part of the mutant protein by the ER quality control system,
leading to reduced expression of the mutant channel in the
sarcolemma.
Thus, the 1493delK mutation shows both loss-of-function, i.e.
reduced sarcolemmal expression, and gain-of-function aspects, i.e.
slowed inactivation kinetics. Since carriers of the 1493delK
mutation present with CCD in the absence of a LQTS phenotype,
it must be concluded that the mild increase in current due to
slowed inactivation is not sufficient to prolong QT-intervals and
that the loss-of-function properties dominate [34]. Hence, the
profound reduction in 1493delK sodium channel expression
results in a lower action potential upstroke velocity with
consequent reduction in conduction velocity, as has also been
described for other mutations linked to CCD [11,35,36].
Although a mutation in the cardiac sodium channel gene is
highly compatible with the clinical phenotype of this family, we
cannot rule out a contribution of mutations in other genes, e.g.
SCN1B [37].
Comparison with other Sodium Channel Mutations
Located in the DIII–DIV Linker
The 1493delK mutation is located in the loop linking domain
III and IV of the sodium channel a-subunit, which mediates fast
inactivation by occluding the intracellular side of the channel pore
shortly following activation [27,38]. Critical to fast inactivation is
the hydrophobic IFM motif (isoleucine–phenylalanine–methio-
nine), the inactivation particle, formed by residues 1485 through
1487. The positively charged lysine residue K1493 is located 6
residues downstream of this IFM motif and forms part of a cluster
of charged residues contained within a a-helical structure. The
DIII–DIV linker is rich of clusters of charged residues, which are
not essential to inactivation, but may modulate deactivation and
fast inactivation kinetics [39]. Over fifteen SCN5A mutations have
been identified in the DIII–DIV linker (Figure 6), leading to either
LQTS (e.g. p.G1481E, p.M1498T, p.1500delK, p.L1501V,
p.1505–1507delKPQ, p.1507–1509delQKP) [40,41,42,43] due
to gain-of-function as a result of residual current [33] or to BrS
(e.g. p.Q1476X, p.K1493X, p.Y1494N, p.1500delK, p.L1501V,
p.G1502S, p.R1512W, p.I1521K) [23,44,45,46,47] as a result of
reduced availability and/or slowing of recovery from inactivation
[33] leading to loss-of-function. Of note, the 1500delK and
L1501V [43,48] mutations are associated with overlap syndromes
of LQTS and BrS (L1501V), and LQTS, BrS and CCD
(1500delK) respectively.
In the set of DIII–DIV linker mutations (Figure 6), two contain
a deletion (or substitution) of a single positively charged residue,
ditto the 1493delK. The 1500delK [48], located in proximity to
the 1493delK contained in the same a-helix downstream of the
IFM motive, and the R1512W [47,49]. Comparing the functional
consequences of these mutant channels with the 1493delK (this
study) reveals both differences and similarities. While sodium
current density was unaltered for 1500delK and R1512W, we
found a profound reduction in peak 1493delK INa amplitude. Of
note, a double mutation at the analogous position in the rat brain
sodium channel SCN3A (KK1441/1442NN), similarly showed
reduced expression [50]. Additionally, the shifts in voltage-
dependence of activation and steady-state inactivation as reported
for 1500delK and R1512W, were absent in 1493delK. However,
the slowing of fast inactivation at voltages positive to ,–40 mV is
a common property to all 3 mutations. Enhancement of a late
current component was only present in the 1500delK mutant
channel, which explains the LQT phenotype in addition to BrS
and CCD in carriers of this mutation.
Conclusion
The deletion mutation 1493delK in the SCN5A gene predisposes
to conduction disease, ventricular arrhythmias and SCD with a
phenotype of P-wave prolongation, AV-block Iu and unspecific
intraventricular conduction delay, without evidence for Brugada
syndrome. The critical underlying mechanism is a five-fold
reduction of sodium current due to a trafficking defect of mutant
NaV1.5 from the ER to the sarcolemma.
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Figure 5. Sodium channel membrane expression in wild-type
and mutant 1493delK SCN5A-transfected HEK293 cells. Confocal
immunofluorescence of the a-subunit of cardiac sodium channel
(NaV1.5) and the endoplasmic reticulum transmembrane protein
calnexin in HEK293 expressing WT (left) and mutant 1493delK (right)
sodium channels. Top and middle panels show staining with anti-
NaV1.5 (green) and anti-calnexin (red) respectively. Bottom panels show
overlay of red and green channels of double staining with anti-NaV1.5
(green) and anti-calnexin (red) antibodies. Membrane labeling for
NaV1.5 is observed as a clearly distinguishable green rim surrounding
the intracellularly located calnexin (red) in WT SCN5A transfected
HEK293 cells, whereas mutant 1493delK SCN5A transfected HEK293 cells
do not show clear cell-surface labeling, but mostly cytoplasmic NaV1.5
staining. Scale bars indicate 25 mm.
doi:10.1371/journal.pone.0067963.g005
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